ELMD vs INGN vs LNTH vs LUNG vs SPXC

For growth investors, Electromed, Inc.

(ELMD) is the stronger pick with 17. 0% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Electromed, Inc. (ELMD) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Lantheus Holdings, Inc.

(LNTH) is the cheapest at 26. 7x versus SPX Technologies, Inc. at 40. 5x. On forward P/E, Lantheus Holdings, Inc. is actually cheaper at 17. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: SPX Technologies, Inc. wins at 1. 37x versus Electromed, Inc. 's 1. 90x — a reasonable growth-adjusted valuation.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to -97. 0% for Pulmonx Corporation (LUNG). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus LUNG's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 47β versus Pulmonx Corporation's 2. 36β — meaning LUNG is approximately 402% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 104% for Pulmonx Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Electromed, Inc.

(ELMD) is pulling ahead at 17. 0% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Electromed, Inc. grew EPS 48. 3% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LUNG leads at 19. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -59. 7% for Pulmonx Corporation — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -59. 3% for LUNG. At the gross margin level — before operating expenses — ELMD leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, SPX Technologies, Inc. (SPXC) is the more undervalued stock at a PEG of 1. 37x versus Electromed, Inc. 's 1. 90x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Lantheus Holdings, Inc. (LNTH) trades at 17. 5x forward P/E versus 26. 1x for SPX Technologies, Inc. — 8. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INGN: 261. 6% to $26. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, SPX Technologies, Inc.

(SPXC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1183% 10Y return). Pulmonx Corporation (LUNG) carries a higher beta of 2. 36 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SPXC: +1183%, LUNG: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ELMD (Healthcare) and INGN (Healthcare) and LNTH (Healthcare) and LUNG (Healthcare) and SPXC (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ELMD is a small-cap high-growth stock; INGN is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; LUNG is a small-cap quality compounder stock; SPXC is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.